Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forty Seven

- PMLiVE

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials' Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.

Innovative Trials

- PMLiVE

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS

- PMLiVE

Genentech and Kronos Bio announce oncology partnership worth over $570m

The companies aim to advance novel therapies for transcriptional targets in oncology

- PMLiVE

AbbVie and Immunome agree on multi-year oncology collaboration

The companies will identify up to ten antibody-target pairs using Immunome's discovery engine

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

- PMLiVE

Kite announces acquisition of Tmunity Therapeutics in latest agreement

The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links